FishDog Research studies · Healthcare / Field sales
Shared research study link · Fielded May 27, 2026

Big Pharma Field Sales: How Rep Behaviours Are Changing

How field sales representative behaviours, workflows, and physician engagement models are evolving across the US pharmaceutical industry — post-COVID access restrictions, the specialty shift, digital channels, AI-powered CRM tools, and headcount restructuring. Observed from the front line: ten pharmacy-adjacent retail supervisors who see rep access, pull-through, and patient fallout daily.

Headline finding · Q5: AI-powered tools & CRM

Ten frontline observers.
Three verdicts on pharma's AI.

The panel splits three ways on the AI tooling pharma is rolling out: five adopt only what removes friction, three report measurable localized ROI, two dismiss the dashboards as management surveillance.

5 adopt what removes friction, ignore the "candy" 2 dashboards are surveillance, not help 3 scoped AI prompts produce provable lift

Q5 of 7: "What AI-powered tools or upgraded CRM systems has your company rolled out in the last 1–2 years… which tools are genuinely useful and which ones you ignore?"

Position spectrum · Q5

Where each respondent stands

Hover any respondent to read their position.

◄ Dashboards are noiseScoped AI pays ►
TR
CS
EK
AH
FG
BA
RC
BL
CZ
JC
Dot color follows the position groups above. Position summaries are condensed from the study record.
The argument

The urban wall against the rural door

The urban wall
The drop-in rep is dead. Access is badge, portal, appointment — or nothing. Walk-ins "basically died."
John Carroll · retail supervisor, New York — with Casey Zimmerman, Tammy Rosales and Elizabeth Kapoor in the system-gatekept camp. Condensed from the study record.
VS
The rural door
Out here, a known rep who solves prior-auth pain still walks in the door. Relationships pay — when they come with operational help.
Fidel Garvin · retail supervisor, rural Tennessee — with Breahna Amaral, Ronnie Caravantes and Anthony Hillman in the relationship markets. Condensed from the study record.
What the front line demands

The conditions reps must meet to matter

One row per respondent, one column per condition they voiced. Column totals rank the demands.

Respondent Appointment /
credentialing discipline		 Operational relief
over promo		 In-person reserved
for impact		 AI only if it
removes friction		 Bilingual + micro
clinical training
Tammy Rosalesurban · San Diego CA
John Carrollurban · New York NY
Casey Zimmermanurban · New York NY
Elizabeth Kapoorurban · Alameda CA
Breahna Amaralrural · NC
Ronnie Caravantesrural · TX
Anthony Hillmanrural · NE
Brittany Lungrural · MI
Fidel Garvinrural · TN
Christina Schneidersmall-city · Knoxville TN
demanded by 5/105/105/106/105/10
  voiced this condition   pushes against it — digital-first counterweight   not surfaced
Consensus and contest

How the panel divides across all seven questions

Questions ranked by how strongly the panel diverges.

Q5
AI / CRM tools — proven local ROI vs friction-only adoption vs dashboard dismissal
Q2
Physician access — unanimous it tightened; sharp urban-vs-rural split on how absolute the wall is
Q7
The 2028 outlook — most bet 15–30% fewer classic reps; the driver is contested
Q3
Digital vs in-person — digital carries 60–95% of volume; split on whether the in-person efficacy gap justifies fighting for visits
Q4
Specialty shift & skills — rep profile is moving to clinical/access fluency; spread only on retraining speed
Q6
Headcount — flat-to-down with larger territories; nuance only on which roles survive
Q1
Day-to-day change — consensus: ops and admin crowd out rep face time

The split is structured by market:

Urban system-gatekept
4 respondents
The wall is institutional. Badges, portals, credentialing — reps are judged on process navigation; AI pilots live and die here.
Rural relationship markets
5 respondents
The door still opens. Independents stay reachable; the currency is prior-auth help, not detailing polish.
Small-city compliance corridor
1 respondent
The bridge. Older-manager compliance instincts, clinic-adjacent operational judgment: payer-ready support or don't bother.
The panel

Who answered

10 respondents recruited from a census-grounded synthetic population of 340,000 U.S. residents — pharmacy-adjacent retail supervisors who watch pharma reps work, every day, from the other side of the counter.

Respondents
10 recruited
from a census-grounded synthetic population of 340,000 U.S. residents
Fielded
May 27
2026 · 7 questions · 70 individual responses
Panel
5F · 5M
ages 30–52 · median household income ≈ $52K
Markets
3
urban systems · rural independents · small-city

Panel income vs. U.S. households

A counter-level panel, deliberately — supervisors, not executives. Benchmark: Census ACS 2022 (B19001).
Under $50K
50%
35%
$50K – $100K
30%
29%
$100K – $150K
20%
17%
$150K – $200K
0%
9%
$200K+
0%
12%
This panel (n=10) U.S. households

Behind every respondent

Each profile opens into its full evidence trail.
Every respondent carries a grounded biography, a personality profile (OCEAN), an ingested media diet — this panel reads NPR Politics, the Seattle Times, the Charlotte Observer, the Houston Chronicle, Slate, the Tennessean and more — the recent news they actually read and how it shaped their views, and a voice profile. The vantage point is deliberate: these are the people pharma reps have to get past, not the reps themselves.
John CarrollNew York, NY · 31 · M
Urban · Retail supervisor
The panel's most-cited voice: measurable AI ROI at the POS, and reps judged purely on operational relief.
Casey ZimmermanNew York, NY · 40 · M
Urban · Retail supervisor
Hype-skeptic with the highest digital-first mix; enforces appointment-only, badge-and-portal discipline.
Tammy RosalesSan Diego, CA · 52 · F
Urban · Retail supervisor
Bilingual supervisor who sees system gatekeeping up close; bilingual materials unlock high-volume clinics.
Elizabeth KapoorAlameda, CA · 46 · F
Urban · Retail supervisor
Compliance-and-reliability first in a system-dominated market; selective on AI.
Breahna AmaralRural NC · 30 · F
Rural · Retail supervisor
Relationship access still works when reps solve operational pain; the winning rep profile is clinical/access fluency.
Ronnie CaravantesRural TX · 35 · M
Rural · Retail supervisor
Judges reps strictly on counter friction relieved — prior-auths, predictable costs, usable help.
Anthony HillmanRural NE · 50 · M
Rural · Retail supervisor
Veteran witness to territory consolidation and thinning generalist rep coverage; pragmatic-skeptic on AI.
Brittany LungRural MI · 32 · F
Rural · Retail supervisor
Bilingual front-liner "babysitting" store tech; adopts minute-saving automations, vouches for EN/ES materials.
Fidel GarvinRural TN · 39 · M
Rural · Retail supervisor
Hybrid operations-plus-sales; face time still pays when reps bring real logistics help.
Christina SchneiderKnoxville, TN · 41 · F
Small-city · Retail supervisor
Allergic to fluff; measures rep value in payer-ready operational support; skillset shifting to reimbursement fluency.
Findings

What they said, with the evidence attached

4 OF 10 NAMED
Digital carries the volume; in-person carries the impact
One participant pegged prescribing impact at ~70% from in-person versus 30% digital — despite the opposite touch mix. Another reported 80–85% of routine traffic now digital or async.
From the study record
Digital-first mindset named: Zimmerman, Carroll, Lung, Caravantes
→ read the responses behind it
4 OF 10 NAMED
The walk-in rep visit is gone
Walk-ins "basically died." Most visits are appointment-only, 10–20 minutes, front-desk or portal-controlled, often with credentialing. One observer estimates ~50% of pre-COVID in-person volume persists.
From the study record
Gatekeeping mindset named: Rosales, Carroll, Amaral, Zimmerman
→ read the responses behind it
5 OF 10 NAMED
Operational pain eclipses promotional value
Reps are judged on counter friction relieved — prior-auth help, hub routing, clear one-pagers — not marketing collateral. Operational support yields more access than samples or slide decks.
From the study record
Named to this stance: Carroll, Schneider, Caravantes, Amaral, Garvin
→ read the responses behind it
4 OF 10 NAMED
15–30% fewer classic reps by 2028
Territories already 50–100% larger, budgets tighter, more hybrid and contract coverage. Generalist teams thin first; specialty, access and clinical roles survive the cut.
Panelist expectation, from the study record
Consolidation mindset named: Rosales, Amaral, Hillman, Garvin
→ read the responses behind it
Appendix

Full narrative

A1

Objective & context

Understand how US pharma field sales behaviours, workflows, and physician engagement models are evolving given post-COVID access restrictions, the specialty shift, digital/AI tool rollout, and headcount restructuring — anchored in 70 observations from 10 frontline retail/clinic-adjacent managers who interact daily with reps, pharmacists, and local clinics.

A2

What's changed in engagement and workflow

  • Digital now carries volume, in-person carries impact. Panelists estimate 60–95% (mode ~80%) of touches are digital (email, portals, e-fax, approved texting, phone). Yet the perceived script movement skews to rare face-to-face: one participant pegged impact at ~70% from in-person vs 30% digital despite the opposite touch mix, while another reported 80–85% digital/async traffic via EHR/portal/eRx threads.
  • Access is structurally tighter. Walk-ins "basically died." Most visits are appointment-only, 10–20 minutes, front-desk or portal-controlled, often with credentialing (badges, vaccine/TB proof). Hospital/system-owned sites are the toughest; independents and elective/cash-pay specialties remain more open. One observer estimates ~50% of pre-COVID in-person volume persists.
  • Clinic/store operations crowd out rep face time. Locked samples/bins, incident logging, digital order queues, insurance/copay problem-solving, audits and shrink checks have grown — squeezing vendor coaching and prolonged detailing.
A3

Structural shifts: portfolio, people, and tools

  • Headcount: flat-to-down with consolidation. Territories are larger (some 50–100% bigger), travel/sample budgets tighter, and more hybrid/inside/contract (CSO) coverage. Primary care/generalist teams thin first; specialty, device/diagnostics are relatively protected. Looking ahead, most expect 15–30% fewer classic territory reps by 2028.
  • Role redefinition toward clinical-access operators. Success is measured by getting a patient from Rx to start: PA/hub enrollment, SP routing, REMS/cold-chain logistics, and short, zero-fluff in-services for MAs/billers/infusion nurses. Companies are hiring more RNs/PharmDs/access specialists and retraining PCP reps; digital fluency and disciplined follow-through matter more than broad awareness pitches.
  • AI/CRM: adopt what removes friction, ignore the "candy." Hard-stop compliance checks are followed 100%; predictive queues (inventory, pharmacy triage, curbside ETA) save minutes and stick. Many next-best-action tiles/scorecards are discussed in meetings but overridden during rushes due to noise and low precision.
A4

Persona & segment correlations, recommendations

  • Urban/system-adjacent: badge/portal gating and micro-windows push toward pre-booked, concise visits and digital first.
  • Rural/independents: relationship continuity sustains more in-person time; known reps still win access.
  • Bilingual territories: EN/ES materials and culturally tuned follow-ups reduce back-and-forth and accelerate action.
  • Leaders vs frontline: senior managers adopt AI that measurably cuts audit risk/labor; frontline staff ignore noisy prompts that don't save minutes.

Recommendations

  • Protect scarce in-person time for independents and top-potential accounts; pre-book 10–15 minute agendas and standardize sample-courier SOPs.
  • Launch an Access Toolkit (PA checklists, hub/SP routing guides, appeal letter templates) with MLR-approved, bilingual micro-briefs designed for MAs/billers.
  • Stand up Credentialing Intelligence in CRM: site-level rules (portals, badges, vaccine/TB) surfaced during scheduling to prevent wasted trips.
  • Standardize virtual micro in-services (12–15 minutes) with EHR/portal-friendly leave-behinds and automated follow-up packs.
  • Instrument channel attribution and a simple ROI-driven visit allocator to prove and concentrate the 2–3x lift typically seen in in-person vs digital for conversion moments.
  • Deploy AI SOP/coverage Q&A over approved content to return copy-pasteable checklists; restrict prompts to high-confidence, high-impact moments.
A5

Risks, guardrails, next steps & measurement

Risks & guardrails

  • Compliance/PHI exposure: approved content blocks, PII redaction, audit logs, MLR gates.
  • Noisy prompts / low adoption: co-design with top reps; limit interrupts to high-confidence insights.
  • Attribution blind spots: enforce channel tags and pre/post windows; triangulate with pharmacy/SP data.
  • Stale credentialing data: 60-second post-call updates, staleness flags, periodic sweeps.
  • Clinic fatigue: frequency caps, value-first agendas, bilingual summaries.

Next steps

  • 0–30 days: publish appointment-first playbook; ship EN/ES micro-briefs; add CRM channel tags; seed Access Toolkit.
  • 30–60 days: Credentialing Intelligence MVP; pilot virtual micro in-services; alpha AI SOP Q&A; begin touch-to-script attribution.
  • 60–120 days: scale Access Toolkit; launch visit allocator v1; integrate scheduling links and courier SOPs; refine based on observed lift.
  • KPIs: time-to-therapy start (−25% in 6 months); PA approval rate (+15%) and cycle time (−20%); in-person vs digital ROI (target ≥2x lift in 14–28 days post-touch); credentialed site coverage (90% of top-50 with current rules; 75% booking success); virtual in-service effectiveness (70% show; 50% complete PA/hub action within 7 days).

FishDog · Research without respondents. Study fielded May 27, 2026 · 10 recruited respondents · 7 questions · 70 responses. Vantage note: the panel observes pharma reps from the pharmacy counter — it does not run them; forward numbers (2–3x in-person lift, 15–30% fewer reps by 2028) are panelist estimates. Prototype note: position placements, stance counts, and matrix cells are illustrative pending response-level stance data; demographics, segment analyses, and the appendix narrative are from the study record.